CGON: CG Oncology, Inc.
Performance
CGON +88.36%
Watchlist
Select an item
Summary
CGON at a glance
CGON returned +88.36% over the past year. Its worst drop in that year was -27.41%, smaller than 63% of stocks on Redstone, and its Sharpe ratio of 1.31 beats 87% of stocks on Redstone. It pays no dividends.
Current Drawdown
-7.36%
Rolling Volatility
69.71%
Actions
Metrics
Risk Indicators
Alpha65.39%
Beta1.07x
Sharpe1.31
Sortino2.40
Omega1.27
Calmar3.22
Martin6.90
Profile
About CGON
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer.
- Sector
- Health Care
- Industry
- Biological Products, (no Diagnostic Substances)
- Market cap
- $6.6B
- Listed
- Jan 2024
- Employees
- 142
- Headquarters
- Dallas, TX
- Website
- cgoncology.com
Comparisons